Skip to main content
CAPRCapricor Therapeutics, Inc.Sell4.5·$8.30
CAPR · Decision

Should you buy Capricor Therapeutics (CAPR)?

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Verdict
SELL
Score
4.5/10
Price
$8.30
Entry / Take Profit (TP) / Stop Loss (SL)
— / $11.01 / $7.72

Engine methodology range

Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.

What the engine is tracking

  • Single Pipeline Concentration→Stable
  • Large Analyst Target UpsideTripped↓Deteriorating
  • Cash Burn Weak Quality→Stable
  • +2 more pillars — see the Why tab for full reasoning

→ Full pillar scorecard with all 5 pillars + per-dimension breakdown

When this thesis breaks

Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Large Analyst Target UpsideTripped

    Trip ifPrice falls below the stop-loss of $8.86 or the analyst target drops below $15.

  • P2Single Pipeline Concentration

    Trip ifRegulator issues a rejection of Deramiocel, dropping price more than 50% in a day.

  • P3Cash Burn Weak Quality

    Trip ifShare count increases by more than 20% from dilution.

  • P4Downtrend Heavy Short Interest

    Trip ifShort interest rises above 45% of float.

  • P5Repeated Earnings Misses

    Trip ifEPS surprise stays below -25% for 2 more consecutive quarters.

How the engine reached this verdict

1. Direct answer

TrendMatrix's engine output for Capricor Therapeutics, Inc. (CAPR) is SELL_IF_HOLDING with medium conviction, score 4.5/10 at $8.30. The death cross gate failed, producing a SELL engine output.

2. Entry, target, and stop

The engine's exit framework anchors to a tactical sell band near $8.30, with structural invalidation at $7.72. The asymmetric R:R against a reversal hypothesis is 0.00 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).

3. What the engine sees

On the bull side: Recent Analyst detected in news. On the bear side: Concentration risk — Pipeline: Deramiocel; Concentration risk — Supplier: donor hearts; DATA_ISSUE: analyst_target_implausible (raw $27.25 vs price $8.30 — ratio 3.3×). Rejected, falling back to technical TP.. Active engine warnings: DATA_ISSUE: analyst_target_implausible (raw $27.25 vs price $8.30 — ratio 3.3×). Rejected, falling back to technical TP., Quality below floor (1.6 < 4.0), V9 Gate Failed: DEATH_CROSS:HARD_BLOCK.

4. What would change the verdict

The dominant failed gate is death cross (HARD_BLOCK). SELL flips back toward HOLD if death cross recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:4.9>=4.5.

For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates CAPR — 10-dimension breakdown →

Bull case

  • ▸Recent Analyst detected in news

Bear case

  • ▸Concentration risk — Pipeline: Deramiocel
  • ▸Concentration risk — Supplier: donor hearts
  • ▸DATA_ISSUE: analyst_target_implausible (raw $27.25 vs price $8.30 — ratio 3.3×). Rejected, falling back to technical TP.
Home › Stocks › CAPR › Buy or sell?